Home >> General Pharmaceuticals >> Housing >> Food & Beverage >>

Diarrhea - Pipeline Review, H1 2015

Published: Jan-2015 | Format: PDF | Global Markets Direct | Number of pages: 171 | Code: MRS - 18395


Global Markets Directs, Diarrhea Pipeline Review, H1 2015, provides an overview of the Diarrheas therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Diarrhea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diarrhea and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

The report provides a snapshot of the global therapeutic landscape of Diarrhea
The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
The report reviews key players involved in the therapeutics development for Diarrhea and enlists all their major and minor projects
The report summarizes all the dormant and discontinued pipeline projects 
A review of the Diarrhea products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
A detailed assessment of monotherapy and combination therapy pipeline projects
Coverage of the Diarrhea pipeline on the basis of target, MoA, route of administration and molecule type
Latest news and deals relating related to pipeline products

Reasons to buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop strategic initiatives by understanding the focus areas of leading companies
Identify and understand important and diverse types of therapeutics under development for Diarrhea
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Devise corrective measures for pipeline projects by understanding Diarrhea pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Content

Table of Contents 2
List of Tables 5
List of Figures 6

Introduction 7
Global Markets Direct Report Coverage 7
Diarrhea Overview 8
Therapeutics Development 9
Pipeline Products for Diarrhea - Overview 9
Pipeline Products for Diarrhea - Comparative Analysis 10
Diarrhea - Therapeutics under Development by Companies 11
Diarrhea - Therapeutics under Investigation by Universities/Institutes 15
Diarrhea - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Diarrhea - Products under Development by Companies 19
Diarrhea - Products under Investigation by Universities/Institutes 22
Diarrhea - Companies Involved in Therapeutics Development 23
A. Menarini Industrie Farmaceutiche Riunite Srl 23
Ache Laboratorios Farmaceuticos S/A 24
Actelion Ltd 25
Aegis Therapeutics, LLC 26
Assembly Biosciences, Inc. 27
Chiesi Farmaceutici SpA 28
Chongqing Zhifei Biological Products Co., Ltd. 29
Cosmo Pharmaceuticals S.p.A 30
Cubist Pharmaceuticals, Inc. 31
DesignMedix, Inc. 32
DiscoveryBiomed, Inc. 33
Furiex Pharmaceuticals, Inc. 34
GlycoVaxyn AG 35
GP Pharm, S.A. 36
Helsinn Healthcare S.A. 37
Intercept Pharmaceuticals, Inc. 38
Ipsen S.A. 39
Mucosis B.V. 40
Napo Pharmaceuticals, Inc. 41
Nippon Shinyaku Co., Ltd. 42
Novartis AG 43
Paratek Pharmaceuticals, Inc. 44
Pfizer Inc. 45
Prokarium Ltd. 46
Sanofi Pasteur SA 47
Scandinavian Biopharma Holding AB 48
Shire Plc 49
Sigmoid Pharma Limited 50
Summit Corporation plc 51
Syntiron LLC 52
Ventria Bioscience 53
Diarrhea - Therapeutics Assessment 54
Assessment by Monotherapy Products 54
Assessment by Target 55
Assessment by Mechanism of Action 58
Assessment by Route of Administration 60
Assessment by Molecule Type 62
Drug Profiles 64
ACE-527 - Drug Profile 64
ACE-920 - Drug Profile 66
ACH-04 - Drug Profile 67
AKT-10081 - Drug Profile 68
ASP-7147 - Drug Profile 69
cadazolid - Drug Profile 70
clostridium difficile vaccine - Drug Profile 71
crofelemer DR - Drug Profile 72
Diarrhea Vaccine - Drug Profile 74
diarrhea vaccine - Drug Profile 75
Drugs for CDAD - Drug Profile 76
elsiglutide - Drug Profile 77
eluxadoline - Drug Profile 78
Escherichia coli vaccine - Drug Profile 80
ETEC Adhesin-Based Vaccine - Drug Profile 81
Etvax - Drug Profile 82
fidaxomicin - Drug Profile 84
GVXNSD-133 - Drug Profile 87
helicobacter pylori vaccine [Hel-305] (multivalent) - Drug Profile 88
ibodutant - Drug Profile 89
infectious diarrhea [serotype H11] (H10407 and E24377A) vaccine - Drug Profile 90
INX-201 - Drug Profile 91
iOWH0-32 - Drug Profile 92
lanreotide acetate - Drug Profile 94
obeticholic acid - Drug Profile 96
octreotide - Drug Profile 99
octreotide acetate MAR - Drug Profile 100
Peptide for Enterocolitis and Infectious Diarrhea - Drug Profile 101
PF-06425090 - Drug Profile 102
prulifloxacin - Drug Profile 103
PZ-7475 - Drug Profile 105
RBX-2660 - Drug Profile 106
Recombinant Peptide to Activate Mucin 3 for Enterocolitis and Infectious Diarrhea - Drug Profile 107
Recombinant Proteins for Infectious Diarrhea - Drug Profile 109
rifamycin - Drug Profile 110
Small Molecule to Inhibit EnaC and Activate CFTR for Cystic Fibrosis, Diarrhea and Autosomal Dominant Polycystic Kidney Disease - Drug Profile 112
Small Molecules for Bacterial Infections - Drug Profile 113
Small Molecules for Diarrhea - Drug Profile 114
Small Molecules for Diarrhea - Drug Profile 115
Small Molecules to Inhibit CFTR for Secretory Diarrhea - Drug Profile 116
SMT-19969 - Drug Profile 117
surotomycin - Drug Profile 118
Tetracycline Derivatives for CDAD - Drug Profile 119
Typhetec - Drug Profile 120
Vaccine for Campylobacter Caused Diarrhea - Drug Profile 121
Vaccine to Target Capsular Vi Polysaccharide Antigen for Traveler's Diarrhea - Drug Profile 123
VEN-100 - Drug Profile 124
VP-20621 - Drug Profile 126
Yersinia pestis vaccine - Drug Profile 127
Diarrhea - Recent Pipeline Updates 128
Diarrhea - Dormant Projects 155
Diarrhea - Discontinued Products 157
Diarrhea - Product Development Milestones 158
Featured News & Press Releases 158

Appendix 166
Methodology 166
Coverage 166
Secondary Research 166
Primary Research 166
Expert Panel Validation 166
Contact Us 167
Disclaimer 167

List of Tables

Number of Products under Development for Diarrhea, H1 2015 13
Number of Products under Development for Diarrhea - Comparative Analysis, H1 2015 14
Number of Products under Development by Companies, H1 2015 16
Number of Products under Development by Companies, H1 2015 (Contd..1) 17
Number of Products under Development by Companies, H1 2015 (Contd..2) 18
Number of Products under Investigation by Universities/Institutes, H1 2015 19
Comparative Analysis by Late Stage Development, H1 2015 20
Comparative Analysis by Clinical Stage Development, H1 2015 21
Comparative Analysis by Early Stage Development, H1 2015 22
Products under Development by Companies, H1 2015 23
Products under Development by Companies, H1 2015 (Contd..1) 24
Products under Development by Companies, H1 2015 (Contd..2) 25
Products under Investigation by Universities/Institutes, H1 2015 26
Diarrhea - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2015 27
Diarrhea - Pipeline by Ache Laboratorios Farmaceuticos S/A, H1 2015 28
Diarrhea - Pipeline by Actelion Ltd, H1 2015 29
Diarrhea - Pipeline by Aegis Therapeutics, LLC, H1 2015 30
Diarrhea - Pipeline by Assembly Biosciences, Inc., H1 2015 31
Diarrhea - Pipeline by Chiesi Farmaceutici SpA, H1 2015 32
Diarrhea - Pipeline by Chongqing Zhifei Biological Products Co., Ltd., H1 2015 33
Diarrhea - Pipeline by Cosmo Pharmaceuticals S.p.A, H1 2015 34
Diarrhea - Pipeline by Cubist Pharmaceuticals, Inc., H1 2015 35
Diarrhea - Pipeline by DesignMedix, Inc., H1 2015 36
Diarrhea - Pipeline by DiscoveryBiomed, Inc., H1 2015 37
Diarrhea - Pipeline by Furiex Pharmaceuticals, Inc., H1 2015 38
Diarrhea - Pipeline by GlycoVaxyn AG, H1 2015 39
Diarrhea - Pipeline by GP Pharm, S.A., H1 2015 40
Diarrhea - Pipeline by Helsinn Healthcare S.A., H1 2015 41
Diarrhea - Pipeline by Intercept Pharmaceuticals, Inc., H1 2015 42
Diarrhea - Pipeline by Ipsen S.A., H1 2015 43
Diarrhea - Pipeline by Mucosis B.V., H1 2015 44
Diarrhea - Pipeline by Napo Pharmaceuticals, Inc., H1 2015 45
Diarrhea - Pipeline by Nippon Shinyaku Co., Ltd., H1 2015 46
Diarrhea - Pipeline by Novartis AG, H1 2015 47
Diarrhea - Pipeline by Paratek Pharmaceuticals, Inc., H1 2015 48
Diarrhea - Pipeline by Pfizer Inc., H1 2015 49
Diarrhea - Pipeline by Prokarium Ltd., H1 2015 50
Diarrhea - Pipeline by Sanofi Pasteur SA, H1 2015 51
Diarrhea - Pipeline by Scandinavian Biopharma Holding AB, H1 2015 52
Diarrhea - Pipeline by Shire Plc, H1 2015 53
Diarrhea - Pipeline by Sigmoid Pharma Limited, H1 2015 54
Diarrhea - Pipeline by Summit Corporation plc, H1 2015 55
Diarrhea - Pipeline by Syntiron LLC, H1 2015 56
Diarrhea - Pipeline by Ventria Bioscience, H1 2015 57
Assessment by Monotherapy Products, H1 2015 58
Number of Products by Stage and Target, H1 2015 61
Number of Products by Stage and Mechanism of Action, H1 2015 63
Number of Products by Stage and Route of Administration, H1 2015 65
Number of Products by Stage and Molecule Type, H1 2015 67
Diarrhea Therapeutics - Recent Pipeline Updates, H1 2015 132
Diarrhea - Dormant Projects, H1 2015 159
Diarrhea - Dormant Projects (Contd..1), H1 2015 160
Diarrhea - Discontinued Products, H1 2015 161

List of Figures

Number of Products under Development for Diarrhea, H1 2015 13
Number of Products under Development for Diarrhea - Comparative Analysis, H1 2015 14
Number of Products under Development by Companies, H1 2015 15
Number of Products under Investigation by Universities/Institutes, H1 2015 19
Comparative Analysis by Late Stage Development, H1 2015 20
Comparative Analysis by Clinical Stage Development, H1 2015 21
Comparative Analysis by Early Stage Products, H1 2015 22
Assessment by Monotherapy Products, H1 2015 58
Number of Products by Top 10 Targets, H1 2015 59
Number of Products by Stage and Top 10 Targets, H1 2015 60
Number of Products by Top 10 Mechanism of Actions, H1 2015 62
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 62
Number of Products by Top 10 Routes of Administration, H1 2015 64
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 64
Number of Products by Top 10 Molecule Types, H1 2015 66
Number of Products by Stage and Top 10 Molecule Types, H1 2015 66

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)2000 View Pricing